drugset / Trial / NCT04313075
A Compassionate Use Study of Leronlimab in Breast Cancer
Summary
This is a single arm, compassionate use study with 30 patients for leronlimab (PRO 140) combined with a treatment of physician's choice (TPC) in patients with CCR5+ mTNBC.
Timeline
- Start
- —
- Primary completion
- —
- Completion
- —
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Leronlimab | Monoclonal antibody | 350 mg | Subcutaneous |
| Subject | Leronlimab | Monoclonal antibody | 525 mg | Subcutaneous |